GE HealthCare Q3 2026 Earnings: Margins Expand as EPS Rises 39%
GE HealthCare reported Q3 2026 revenue of $5.513 billion, up 7.2% year over year, with GAAP diluted EPS rising 39.1% to $1.36. Profitability expanded across all segments, driven by volume, pricing, cost productivity, and favorable tariff effects, lifting the adjusted EBIT margin by 180 basis points to 16.6%. Operating cash flow reached $907 million. Following solid year-to-date execution, management raised its full-year organic revenue growth outlook to approximately 4.0% and increased its free-cash-flow target to at least $1.6 billion, while ongoing risks include slower order growth, inflation, working-capital consumption from inventory, and the pending SOFIE Biosciences acquisition.
GE HealthCare (Nasdaq: GEHC) reported Q3 2026 revenue of $5.513 billion, up 7.2% year over year, while GAAP diluted EPS rose 39.1% to $1.36 from $0.98. Profitability expanded across all three segments, and quarterly operating cash flow increased to $907 million, although it included a $55 million tariff refund. Organic revenue grew 6.2%, while organic orders increased 4.0%, book-to-bill reached 1.03, and backlog stood at $23.7 billion.
Core Financial Results
GE HealthCare generated growth across each reporting segment in the quarter ended September 30, 2026. Profit increased faster than revenue as volume, pricing, cost productivity, and a favorable year-over-year net tariff effect outweighed inflationary pressure.
Both GAAP and adjusted profitability improved. Net income attributable to GE HealthCare increased 37.9%, while adjusted EBIT rose 19.9% and adjusted EPS advanced 25.1%.
| Metric | Q3 2026 | Q3 2025 | YoY Change |
|---|---|---|---|
| Revenue | $5,513 million | $5,143 million | +7.2% |
| Gross profit and margin | $2,224 million; about 40.3% | $1,990 million; about 38.7% | +11.8%; margin up about 160 bps |
| Operating income and margin | $805 million; about 14.6% | $653 million; about 12.7% | +23.3%; margin up about 190 bps |
| Net income attributable to GE HealthCare | $615 million | $446 million | +37.9% |
| Diluted EPS | $1.36 | $0.98 | +39.1% |
| Adjusted EBIT and margin | $913 million; 16.6% | $761 million; 14.8% | +19.9%; margin up 180 bps |
| Adjusted EPS | $1.34 | $1.07 | +25.1% |
| Operating cash flow | $907 million | $593 million | Up $314 million |
| Free cash flow | $793 million | $483 million | Up $310 million |
Gross and operating margins are approximate calculations based on reported rounded amounts. Adjusted EBIT, adjusted EPS, and free cash flow are non-GAAP measures.
Business and Segment Performance
Pharmaceutical Diagnostics delivered the fastest revenue growth, while Advanced Imaging Solutions remained the largest segment and produced the largest amount of segment EBIT. Patient Care Solutions recorded the largest margin improvement, with segment EBIT more than doubling from the prior-year quarter.
| Segment | Revenue | Reported Growth | Organic Growth | Segment EBIT | EBIT Margin |
|---|---|---|---|---|---|
| Advanced Imaging Solutions | $3,873 million | +6.1% | +4.5% | $593 million, +15.8% | 15.3%, up 130 bps |
| Pharmaceutical Diagnostics | $846 million | +13.0% | +13.8% | $253 million, +14.9% | 29.9%, up 50 bps |
| Patient Care Solutions | $793 million | +8.5% | +8.8% | $68 million, +148.8% | 8.6%, up 480 bps |
Patient Care Solutions is also undergoing a leadership transition. Jeannette Bankes is leaving to become CEO of another publicly traded company, and Neal Sandy will become the segment’s president and CEO on November 16, 2026.
Demand indicators remained positive but grew more slowly than revenue. Organic orders increased 4.0%, compared with 6.2% organic revenue growth, while the 1.03 book-to-bill ratio indicated that quarterly orders remained slightly above revenue.
Profitability, Cash Flow and Balance Sheet
Adjusted EBIT margin expanded by 180 basis points to 16.6%. Management attributed the improvement to higher volume, pricing, cost productivity, and a favorable year-over-year net tariff effect, partially offset by inflation. The adjusted EBIT reconciliation excluded a $9 million pre-tax tariff refund from the quarter.
Cash generation also improved, but the tariff benefit affected comparability. Operating cash flow and free cash flow each included a $55 million tariff refund. Capital expenditures were $114 million, compared with $110 million a year earlier.
At quarter-end, GE HealthCare had $2.9 billion of cash and cash equivalents, access to $3.5 billion of revolving credit facilities, and $10.0 billion of outstanding debt. The company also plans to pay $945 million in cash for SOFIE Biosciences, with closing expected in the first half of 2027 subject to regulatory approvals and other customary conditions.
Inventory reached $2.628 billion at September 30, up from $2.234 billion at the end of 2025. For the first nine months of 2026, inventory growth represented a $430 million use of operating cash.
2026 Guidance
GE HealthCare raised or narrowed several full-year targets following its improved year-to-date performance. The organic revenue outlook moved to approximately 4.0%, while the lower ends of the adjusted EBIT margin and adjusted EPS ranges increased. The company also raised its free-cash-flow target to at least $1.6 billion.
| Metric | Updated 2026 Guidance | Previous Guidance | Change |
|---|---|---|---|
| Organic revenue growth | Approximately 4.0% | 3.0%-4.0% | Raised to the top of the prior range |
| Adjusted EBIT margin | 15.5%-15.7% | 15.4%-15.7% | Lower end increased by 10 bps |
| Adjusted effective tax rate | 20.0%-21.0% | 20.0%-21.0% | Reaffirmed |
| Adjusted EPS | $4.95-$5.05 | $4.80-$5.00 | Range increased |
| Free cash flow | $1.6 billion or more | Approximately $1.6 billion | Raised |
The outlook is presented on a non-GAAP basis.
Risks Investors Need to Watch
- Orders are growing more slowly than revenue: Organic orders rose 4.0% compared with 6.2% organic revenue growth. Although book-to-bill remained above 1.0 and backlog totaled $23.7 billion, order growth and backlog conversion will be important for sustaining revenue momentum.
- Inflation remains a margin offset: Volume, pricing, productivity, and tariff effects improved profitability, but management identified inflation as a partial offset to those gains.
- Tariff refunds affected cash-flow comparability: Quarterly operating cash flow and free cash flow included a $55 million refund, making the underlying improvement smaller than the reported increase.
- Inventory is consuming working capital: Inventory increased by about 18% from year-end, and the build used $430 million of cash during the first nine months of 2026.
- Capital commitments and segment leadership changes require monitoring: GE HealthCare carries $10.0 billion of debt and plans a $945 million cash acquisition, while Patient Care Solutions will transition to a new leader after delivering a substantial quarterly margin improvement.
Summary
GE HealthCare’s Q3 2026 results combined broad segment revenue growth with faster profit growth and higher cash generation. Volume, pricing, productivity, and favorable tariff effects supported margin expansion, while inflation and working-capital demands remained offsets. The raised full-year outlook reflects stronger year-to-date execution, with future order growth, cash conversion, inventory, and the planned SOFIE acquisition among the main areas to monitor.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.